Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;2(3):75-83.
doi: 10.46439/allergy.2.028.

Possible therapeutic targets for SARS-CoV-2 infection and COVID-19

Affiliations

Possible therapeutic targets for SARS-CoV-2 infection and COVID-19

Nabab Khan et al. J Allergy Infect Dis. 2021.

Abstract

SARS-CoV-2 infection causes COVID-19, which has emerged as a health emergency worldwide. SARS-CoV-2 infects cells by binding to ACE2 receptors and enters into the cytoplasm following its escape from endolysosomes. Once in the cytoplasm, the virus replicates and eventually causes various pathological conditions including acute respiratory distress syndrome (ARDS) that is caused by pro-inflammatory cytokine storms. Thus, endolysosomes and cytokine storms are important therapeutic targets to suppress SARS-CoV-2 infection and COVID-19. Here, we discuss therapeutic targets of SARS-CoV-2 infection and available drugs that could be helpful in the suppression of the SARS-CoV-2 infection and pathological condition COVID-19. The urgency of the COVID-19 pandemic precludes the development of new drugs and increased focus on drug repurposing might provide the quickest way to finding effective medicines.

Keywords: ARDS (Acute Respiratory Distress Syndrome); COVID-19 (Coronavirus Infectious Disease-19); Cytokine Storm; Endolysosomes; SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest No Conflict of Interest.

Similar articles

References

    1. CoViD-19 (2019-nCoV) Data Repository by Johns Hopkins University Center for Systems Science and Engineering (JHU CSSE). 2020.
    1. Guy RK, DiPaola RS, Romanelli F, Dutch RE. Rapid repurposing of drugs for COVID-19. Science. 2020. May 22;368(6493):829–30. - PubMed
    1. Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19. Cellular Signalling. 2020. Oct 1;74:109721. - PMC - PubMed
    1. Hussman JP. Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention. Frontiers in Pharmacology. 2020. Jul 29;11:1169. - PMC - PubMed
    1. Khan N, Chen X, Geiger JD. Role of endolysosomes in severe acute respiratory syndrome coronavirus-2 infection and coronavirus disease 2019 pathogenesis: implications for potential treatments. Frontiers in Pharmacology. 2020. Oct 29;11:1739. - PMC - PubMed

LinkOut - more resources